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Cost-eﬀ ectiveness of female human papillomavirus 
vaccination in 179 countries: a PRIME modelling study
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Summary
Background Introduction of human papillomavirus (HPV) vaccination in settings with the highest burden of HPV is 
not universal, partly because of the absence of quantitative estimates of country-speciﬁ c eﬀ ects on health and 
economic costs. We aimed to develop and validate a simple generic model of such eﬀ ects that could be used and 
understood in a range of settings with little external support.
Methods We developed the Papillomavirus Rapid Interface for Modelling and Economics (PRIME) model to assess 
cost-eﬀ ectiveness and health eﬀ ects of vaccination of girls against HPV before sexual debut in terms of burden of 
cervical cancer and mortality. PRIME models incidence according to proposed vaccine eﬃ  cacy against HPV 16/18, 
vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine 
protection and no changes to other screening programmes or vaccine uptake. We validated PRIME against existing 
reports of HPV vaccination cost-eﬀ ectiveness, projected outcomes for 179 countries (assuming full vaccination of 
12-year-old girls), and outcomes for 71 phase 2 GAVI-eligible countries (using vaccine uptake data from the GAVI 
Alliance). We assessed diﬀ erences between countries in terms of cost-eﬀ ectiveness and health eﬀ ects. 
Findings In validation, PRIME reproduced cost-eﬀ ectiveness conclusions for 24 of 26 countries from 17 published 
studies, and for all 72 countries in a published study of GAVI-eligible countries. Vaccination of a cohort of 58 million 
12-year-old girls in 179 countries prevented 690 000 cases of cervical cancer and 420 000 deaths during their lifetime 
(mostly in low-income or middle-income countries), at a net cost of US$4 billion. HPV vaccination was very cost 
eﬀ ective (with every disability-adjusted life-year averted costing less than the gross domestic product per head) in 
156 (87%) of 179 countries. Introduction of the vaccine in countries without national HPV vaccination at present would 
prevent substantially more cases of cervical cancer than in countries with such programmes, although the disparity 
has narrowed since 2012. If 71 phase 2 GAVI-eligible countries adopt vaccination according to forecasts, then in 
2070 GAVI Alliance-funded vaccination could prevent 200 000 cases of cervical cancer and 100 000 deaths in some of 
the highest-burden countries.
Interpretation Large between-country disparities exist for HPV vaccination, with countries with the most to gain yet 
to introduce national HPV vaccination. Support from the GAVI Alliance could help to reduce such disparities, but a 
substantial burden will remain even after presently projected vaccine introductions.
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Introduction
Estimates of the possible health and economic eﬀ ects of 
human papillomavirus (HPV) vaccination provide vital 
evidence to support the introduction of the vaccine into 
national programmes. WHO recommends that cost-
eﬀ ectiveness is considered before introduction of the 
vaccine,1 and many high-income countries started such 
assessments before introduction.2 In low-income and 
middle-income countries (LMICs), such assessments 
are less common, but are equally, if not more, important 
because of insuﬃ  cient funding for public health 
interventions and the need to establish the ﬁ nancial 
case for vaccination to ministries of ﬁ nance.3 For 
example, the cost of the entire Expanded Programme on 
Immunization vaccine schedule (Bacillus Calmette-
Guérin, diphtheria-tetanus-pertussis, oral polio, and 
measles) was estimated to be about US$17 per fully 
vaccinated child.4 Conversely, the price for three doses 
of HPV vaccine was estimated to be about $13·50 
through GAVI Alliance procurement, $39 at the lowest 
non-GAVI public sector indicative price, and more than 
$300 in high-income countries.5 Some reports have 
suggested that overinvestment in vaccines for low-
burden diseases in LMICs has prevented vaccines 
against diseases of greater public health concern from 
being introduced.6 To avoid misplaced priorities, many 
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international funders such as the GAVI Alliance are 
guided by forecasts of the eﬀ ect of disease and cost-
eﬀ ectiveness to decide which vaccination programmes 
to fund.7
However, assessments of cost-eﬀ ectiveness of HPV 
vaccination often use complex models with data and 
expertise requirements that are prohibitive in many 
settings. Application of such models to resource-poor 
settings might require dependence on external 
consultants, which can sometimes restrict the 
involvement of local analysts and policy makers and, 
consequently, the eﬀ ect that these results have on local 
decisions.3 Furthermore, existing analyses have been 
done with various model types, ranging from simple 
static models that only consider direct eﬀ ects, to complex 
individual-based transmission dynamic models. This 
variation in model types restricts the comparability of 
their results,8–10 because diﬀ erent model types rely on 
diﬀ erent simplifying assumptions.
To address this knowledge gap and support evidence-
based vaccine introduction in countries without reliable 
economic assessments of HPV vaccination, we aimed to 
develop a generic model of the health and economic 
eﬀ ects of female HPV vaccination that uses straightforward 
calculations and data requirements and transparent 
assumptions so that it can be used and understood in a 
range of settings with little external support.
We also aimed to validate the model against other 
published HPV models, assess the cost-eﬀ ectiveness of 
HPV vaccination in 179 countries with a particular focus 
on LMICs, and forecast reduction in the global cervical 
cancer burden and health disparities after HPV 
vaccination, with diﬀ erent vaccine uptake scenarios 
including GAVI Alliance strategic demand forecasts.
Methods
Model overview
We developed the Papillomavirus Rapid Interface for 
Modelling and Economics (PRIME) as a Microsoft Excel-
based model that estimates the health and economic 
eﬀ ect of vaccination of girls against HPV before sexual 
debut. We modelled the eﬀ ect of the vaccine in terms of 
reduction in age-dependent incidence of cervical cancer 
and mortality in direct proportion to vaccine eﬃ  cacy 
against HPV 16/18, vaccine coverage, and HPV type 
distribution (appendix p 1). We assumed that no changes 
to methods of cervical cancer screening or uptake occur 
during the time horizon of the model—ie, the period 
during which model results are followed (in most cases, 
the lifetime of the vaccinated cohort). We further 
assumed that vaccines provide lifelong protection, as 
suggested by the absence of vaccine failures in long-
term follow-up of vaccinated cohorts, and statistical 
extrapolation of immunogenicity data.11 We did not 
consider indirect eﬀ ects (herd protection), thus the 
model provides a conservative lower bound on vaccine 
eﬀ ect.
Validation  
To assess validity of our model, we used PRIME to 
replicate results of all relevant published cost-eﬀ ectiveness 
analyses of HPV vaccination in LMICs, as identiﬁ ed in a 
recent systematic review.8 We extracted key parameters 
(vaccination coverage, vaccine eﬃ  cacy, vaccination age, 
cost per vaccinated girl, cost of cervical cancer treatment, 
discount rate, age-dependent mortality, age-dependent 
cervical cancer mortality, cervical cancer incidence, and 
HPV 16/18-dependent fraction of cervical cancers) from 
every study and used these as input parameters for 
PRIME. We used Cohen’s kappa to test agreement 
between PRIME and published models about whether 
vaccination was very cost eﬀ ective in the countries 
examined. To further assess validity, we made a separate 
comparison with results of a cost-eﬀ ectiveness analysis of 
HPV vaccination in the GAVI-72 countries (countries that 
are eligible for GAVI Alliance support in phase 2 of their 
strategic plan [2006–10]).12 Appendix pp 2–10 gives further 
details about study selection and data extraction.
Projections for 179 countries  
We parameterised PRIME with data from 179 countries 
for which UN population estimates are available.13 Data 
for size of vaccination cohort, likely vaccine procurement 
and administration costs, incidence of cervical cancer, 
treatment costs, all-cause and cervical cancer-speciﬁ c 
mortality, gross domestic product (GDP) per head, and 
proportion of cancers due to HPV16 and HPV18 were 
obtained from global datasets produced by WHO, the 
World Bank, the International Agency for Research on 
Cancer, and other sources (appendix pp 2–10).13–20
We estimated the eﬀ ect of vaccination of the entire 
cohort (58 million 12-year-old girls) in terms of the 
number of cases of cervical cancer, deaths, and disability-
adjusted life-years (DALYs) averted during their lifetimes. 
We assumed full vaccination coverage of the relevant 
cohort for illustrative purposes. We measured cost-
eﬀ ectiveness by comparing the cost per DALY averted 
(in 2011 US$) with thresholds of GDP per head, which is 
often used as an indication that an intervention is very 
cost eﬀ ective, and three times GDP per head, used to 
indicate that an intervention is cost eﬀ ective.21 We did 
sensitivity analyses by varying key parameters (vaccine 
costs, cancer costs, cancer incidence, and cancer mortality) 
by plus or minus 25%, with cancer incidence and mortality 
from 2008 estimates (rather than 2012), and setting 
discount rates to 0% or 6%. We also explored the eﬀ ect of 
adjustment of regional cancer costs by country-level 
variation in GDP per head (in 2011 US$; appendix p 6).
To explore between-country equity of present use of 
HPV vaccines, we estimated the potential eﬀ ect of HPV 
vaccination on reduction of the burden of cervical cancer 
for countries that had introduced country-wide 
vaccination by Jan 1, 2012, and by Oct 1, 2013, and 
countries that are yet to introduce vaccination nationwide. 
National vaccines introduced by 2012 were determined 
See Online for appendix
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from data by Markowitz and colleagues,22 whereas intro-
ductions by October, 2013, were obtained from WHO 
(Wang S A, WHO, personal communication). We did a 
similar analysis to explore associations between eﬀ ect of 
vaccine and presence of an existing cost-eﬀ ectiveness 
evaluation of HPV vaccination, as reported in the four 
most recent systematic reviews of HPV vaccination.8,23–25 
We included studies focusing only on one country or a 
small number of countries (fewer than ten in the same 
publication).
To assess the quality of model parameters, we rated 
data for cancer incidence, cancer mortality, distribution 
of HPV type in cancer, and distribution of cancer stage 
at detection for every country as either “satisfactory” or 
“unsatisfactory”. Ratings were based on whether 
representative, good quality within-country data were 
available (appendix pp 6, 7, 25–30).
Projections for GAVI countries  
The GAVI Alliance produced HPV vaccination coverage 
estimates for 2009–12 and strategic demand forecasts to 
2032 for 73 countries (the GAVI-72 countries and South 
Sudan; Johnson H, GAVI Alliance, personal com-
munication). We extrapolated ﬁ gures (obtained with 
permission from the GAVI Alliance) for 71 countries (all 
except South Sudan and Kiribati, for which population 
projections were not available) by assuming that the 
proportion of 12-year-old girls who received HPV 
vaccination remained at the ﬁ gures for 2032, even though 
the absolute number of doses would change because of 
ﬂ uctuations in the size of the 12-year-old female 
population. We then used these forecasts as inputs to 
PRIME (together with existing inputs for disease burden) 
to project the eﬀ ect of vaccine on cervical cancer cases 
and deaths. We did sensitivity analyses by varying cancer 
incidence and mortality by plus or minus 25%. We 
modelled 61 vaccinated cohorts in these 71 GAVI-72 
countries (one for every year from 2009–70), and 
aggregated the projected future eﬀ ect of vaccination of 
every cohort to produce results by calendar year. In 
addition to this base case scenario, we also considered 
the eﬀ ect of other scenarios: ﬁ rst, no further vaccine 
introductions or increases in coverage beyond 2014 
(worst case); second, vaccine introductions and increases 
in coverage in 2012–32 based on GAVI Alliance strategic 
demand forecasts (middle variant); and third, the entire 
cohort of 12-year-old girls in every GAVI-72 country is 
vaccinated every year from 2014 (best case).
Role of the funding source  
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The views expressed are those of the authors and do not 
necessarily represent the views of WHO. RH is a staﬀ  
member of WHO. The corresponding author had full 
access to all data in the study and ﬁ nal responsibility for 
the decision to submit for publication.
Results
In our validation assessment, PRIME generally provided 
incremental cost-eﬀ ectiveness ratios that were very close to 
those of the original country-based study when the original 
study parameters were used (ﬁ gure 1). With a threshold of 
GDP per head as very cost eﬀ ective, PRIME reproduced 
the qualitative conclusions (in terms of vaccination being 
very cost eﬀ ective or not) for 24 of 26 countries (k=0·85) in 
17 published studies. For the GAVI-72 analysis, both 
PRIME and Goldie and colleagues12 produced much the 
same conclusion for all 72 (k=1) countries: female HPV 
vaccination would be very cost eﬀ ective in all countries 
except Afghanistan and the Democratic Republic of Congo. 
Appendix pp 17–24 shows the full results.
Vaccination of a cohort of 58 million girls before sexual 
debut, which represents full coverage in 179 countries of 
Figure 1: Comparison of estimated incremental cost-eﬀ ectiveness ratios (ICERs) between Papillomavirus Rapid 
Interface for Modelling and Economics (PRIME) and published literature for HPV vaccination of young girls
(A) In 26 countries with low and middle incomes examined in 17 studies and (B) in GAVI-72 countries examined in 
Goldie and colleagues.12 The diagonal line shows perfect agreement between PRIME and original paper ICERs.
Appendix pp 11–16 shows deﬁ ntions of two-letter country abbreviations. DALY=disability-adjusted life year.
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12-year-old girls, would prevent 690 000 cases and 
420 000 deaths related to cervical cancer during the 
lifetime of the cohort, at a net cost of US$4 billion 
(appendix pp 15–24 shows the results by country). Most 
prevented cancers (480 000 [70%]) and deaths 
(310 000 [75%]) would occur in countries with low or lower-
middle income (table 1).
Figure 2 shows the number of prevented cervical 
cancers per 100 000 girls vaccinated for countries with 
and without national HPV vaccination programmes. Of 
33 countries where HPV vaccines are likely to have the 
greatest eﬀ ect (>2500 cancers prevented per 100 000 girls 
vaccinated), only four had introduced national vaccination 
by Jan 1, 2012 (Fiji, Peru, Romania, and Rwanda), and an 
additional three had between Jan 1, 2012, and Oct 1, 2013 
(ﬁ gure 2). Conversely, of 55 countries where HPV 
vaccines are likely to have the least eﬀ ect in comparison 
(<1000 cancers prevented per 100 000 girls vaccinated; 
mostly in western Europe and North America), 24 have 
introduced vaccination.
The number of cancers that could be prevented per 
100 000 girls vaccinated was signiﬁ cantly lower (2-sided 
t test p=0·011) in the 46 countries that have introduced 
national vaccination (2013: median 980, IQR 700–1700) 
than in the 133 countries that have not (1600, 1000–2300; 
ﬁ gure 3). The disparity is seen in every WHO region 
except the African Region (ﬁ gure 3). However, world-
wide, the disparity narrowed between 2012 and 2013, 
when the number of cancers that could be prevented per 
100 000 girls vaccinated in the 34 countries with national 
vaccination was lower (median 930, IQR 690–1200) than 
in 2013. The improvement has mainly been because of 
new vaccine introductions in the African and Americas 
regions since 2012.
Vaccinated 
girls (millions)
Vaccine cost 
(US$, millions)
Net cost 
(US$, millions)
Cancers 
prevented
(thousands)
Deaths 
prevented
(thousands)
Proportion of 
all prevented 
cancers
Proportion of 
all prevented 
deaths
World 58·1 4500 4100 690 420 100·0% 100·0%
Southeast Asian Region 17·0 500 390 240 150 35·6% 36·6%
African Region 10·8 300 200 200 130 28·4% 31·6%
Region of the Americas 7·5 1200 1100 110 56 15·5% 13·3%
Western Paciﬁ c Region 11·6 990 930 72 42 10·5% 10·0%
European Region 4·9 1100 1100 39 17 5·7% 4·2%
Eastern Mediterranean region 6·2 380 360 29 18 4·2% 4·3%
Low-income countries 9·7 190 130 160 110 23·7% 27·3%
Lower-middle-income countries 24·8 820 670 320 200 46·8% 47·5%
Upper-middle-income countries 17·6 970 830 170 90 24·4% 21·4%
High-income countries 6·1 2500 2500 35 16 5·1% 3·8%
Table 1: Eﬀ ect of vaccination of one birth cohort of 12-year-old girls
Figure 2: Estimated number of cervical cancers prevented per 100 000 girls vaccinated against human papillomavirus (HPV) in 186 countries
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When parameterised with global data, HPV vaccination 
of young girls is cost-eﬀ ective (less than three times GDP 
per head) in all but six countries (mostly in the Eastern 
Mediterranean region) with low reported incidence of 
cervical cancer compared with other countries with 
similar income, and very cost-eﬀ ective (below GDP per 
head) in 156 (87%) of 179 countries (appendix pp 15–24).
Projections of the quality of data that informs most 
high-income countries and some middle-income countries 
(including China, Brazil, Argentina, and South Africa) was 
judged satisfactory in all categories assessed. However, 
data quality for most countries in African and Eastern 
Mediterranean regions and Central Asia was judged 
unsatisfactory in almost all categories assessed 
(appendix pp 25–30).
In the sensitivity analyses, our overall results were robust 
to adjustments to any of the key parameters apart from 
discount rates (table 2); across all scenarios HPV 
vaccination was cost-eﬀ ective in all but three to eight 
countries. However, discount rates have a large eﬀ ect; 
setting discount rates to 0% makes vaccination cost 
eﬀ ective in all countries (and very cost eﬀ ective in all but 
three countries), whereas setting it to 6% makes vaccination 
not cost eﬀ ective in 26 countries (table 2).
In terms of association between vaccine introduction 
and previous cost-eﬀ ectiveness assessment, presence of a 
published economic evaluation of HPV vaccination was 
strongly associated with having introduced a universal 
vaccination programme. Only 28 (18%) of 153 countries 
without published economic evaluations had universal 
vaccination programmes. These countries mainly had 
upper-middle incomes or were high income with small 
populations (such as Greece, New Zealand, Romania, 
Sweden, and the United Arab Emirates). Only four 
countries with low and lower-middle income fell into this 
category (Bhutan, Fiji, the Federated States of Micronesia, 
Figure 3: Eﬀ ect of vaccine (potential number of cervical cancers prevented per 100 000 girls vaccinated) in countries that have and have not introduced national vaccination (for which there 
are at least two countries in the relevant category)
Data show year of vaccine introduction, median cancers avoided per 100 000 vaccinated (IQR), and number of countries. The horizontal axis shows all countries in the relevant category arranged in 
increasing order of vaccine eﬀ ect, so a high line shows a high burden of preventable disease.
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and Rwanda). By contrast, 18 (70%) of 26 countries with 
published economic evaluations had universal vaccination 
programmes.
Figure 4 shows the projected eﬀ ect of HPV vaccination 
in the GAVI-72 countries, assuming that they adopt 
vaccination on the schedule suggested by GAVI Alliance 
strategic demand forecasts. According to these forecasts, 
vaccine demand in GAVI-72 countries is likely to increase 
sharply in 2015–20; this increase is likely to produce large 
reductions in incidence and mortality of cervical cancer 
after 2050 (ﬁ gure 4). By 2070, vaccination could prevent 
almost 200 000 cases of cervical cancer and more than 
100 000 deaths every year. Equivalent ﬁ gures for 2030 are 
9000 cancers and 3000 deaths prevented, and for 2050 are 
40 000 cancers and 20 000 deaths prevented. These 
projections assume that no related interventions (such as 
cervical screening or increased access to cancer treatment) 
are introduced where they did not previously exist. If all 
GAVI-72 countries are able to adopt HPV vaccination in 
2014 with complete coverage, then the maximum eﬀ ect of 
global vaccine would be 400 000 fewer cases of cervical 
cancer and 200 000 fewer deaths every year by 2070. The 
largest country contributing to the diﬀ erence is India, 
which at present is not forecast to introduce HPV 
vaccination. If no new vaccines are introduced after 2013, 
then only around 2000 cervical cancer cases and 
1000 cancer deaths will be prevented every year after 2070 
in GAVI-72 countries.
Discussion
To our knowledge, this study is the ﬁ rst assessment of the 
likely health and economic eﬀ ect of female HPV 
vaccination in 179 countries. By use of a straightforward 
model, which was validated against existing cost-
eﬀ ectiveness studies in LMICs, we report that HPV 
vaccination is likely to be very cost eﬀ ective in most 
countries and cost-eﬀ ective in almost every country in the 
world (panel). Furthermore, cost eﬀ ectiveness of HPV 
vaccination could be better than presented, once further 
beneﬁ ts not included in our analysis are incorporated 
such as herd protection, protection against non-cervical 
cancers and genital warts (in both females and males), 
and cost savings as a result of reduced need for cervical 
screening and treatment. Moreover, in high-income 
countries, which publicly procure HPV vaccines through 
competitive tenders, vaccine purchase prices could be 
substantially lower than the US retail price assumed. 
Hence a country’s failure to show cost-eﬀ ectiveness in this 
analysis is an indication that cost-eﬀ ectiveness of HPV 
vaccination needs to be investigated more closely in that 
country before introduction of a vaccination programme, 
rather than as a reason to rule out vaccination.
Only three economic evaluations of HPV vaccination 
on a multiregional scale have been published.12,16,26 Two 
reviews12,16 were done before GAVI Alliance support for 
HPV vaccine introduction was announced. Ginsberg and 
colleagues16 assessed the cost-eﬀ ectiveness of female 
HPV vaccination by WHO subregion using a state 
transition model, but did not provide assessments of 
eﬀ ect or cost-eﬀ ectiveness at country (rather than 
regional) level. Goldie and colleagues12 assessed the cost-
eﬀ ectiveness of HPV vaccination in 72 low-income 
countries. Both these assessments used more complex 
models than did ours; however, their results agree with 
our overall conclusions that HPV vaccination is likely to 
be very cost eﬀ ective in most parts of the world. A third 
global analysis was published more recently,26 but again 
this study did not provide country-level assessments. 
Furthermore, this analysis26 mainly extrapolated data 
from high-income and middle-income countries, so its 
 Vaccine cost 
(US$, millions)
Net cost 
(US$, millions)
Cancers 
prevented 
(thousands)
Deaths 
prevented 
(thousands)
Not cost 
eﬀ ective (n)
Cost eﬀ ective 
(n)
Very cost 
eﬀ ective (n)
Base case 4500 4100 690 420 6 17 160
Vaccine cost +25% 5600 5200 690 420 7 29 140
Vaccine cost –25% 3400 3000 690 420 5 11 160
Cancer cost GDP-adjusted 4500 4100 690 420 6 17 160
Cancer cost +25% 4500 4000 690 420 6 17 160
Cancer cost –25% 4500 4200 690 420 6 17 160
Cancer incidence +25% 4500 4000 860 420 6 17 160
Cancer incidence –25% 4500 4200 510 420 6 20 150
Cancer incidence 2008 
cancer estimates
4500 4000 760 480 3 20 160
Cancer mortality +25% 4500 4100 690 520 5 12 160
Cancer mortality –25% 4500 4100 690 310 8 32 140
Discount rate 6% 4500 4100 690 420 26 55 98
Discount rate 0% 4500 4100 690 420 0 3 180
GDP=gross domestic product per head.
Table 2: Eﬀ ect of variations in key parameters of vaccination of an entire 12-year-old cohort
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validity in low-income countries where most cervical 
cancer burden lies is uncertain. In addition to these 
multiregional models, a series of regional cost-
eﬀ ectiveness analyses of HPV vaccination have been 
published for sub-Saharan Africa,27 the Middle East,28 
North Africa,28 Central Europe,29 Eastern Europe,29 and 
Central Asia.29
Our study is unique in its assessment of the eﬀ ect and 
cost-eﬀ ectiveness of HPV vaccination at country level in 
almost every country worldwide, with a particular focus 
on low-income countries and intercountry disparities. 
One limitation is that we have, out of necessity, relied 
on global datasets instead of data collected within every 
country. We note that for many countries (especially in 
African and Eastern Mediterranean regions) data quality 
are poor and often extrapolated from other countries in 
the region. Hence, we might not have comprehensively 
addressed between-country variations within the same 
region and income. Consequently, our results should be 
used mainly to understand between-region variations 
and not to inform decisions on a national level. For 
national decisions, PRIME can be used as a technique 
to guide country-led data collection to inform more 
contextualised results.
Our validation exercise shows that PRIME provides 
similar results to those obtained by more complex cost-
eﬀ ectiveness models for evaluation of HPV vaccination of 
girls before sexual debut. To our knowledge, our model is 
the ﬁ rst to be validated by quantitative comparison of 
results with such a broad range of published models. 
Admittedly, many of the modelling studies in the 
published work have used the same model or are 
adaptations of previous models.8 However, the consistency 
of our results with almost all literature suggests that the 
eﬀ ect and cost-eﬀ ectiveness of vaccinating girls before 
sexual debut at high coverage can be reasonably predicted 
from data for cancer incidence, distribution of HPV type 
in cancer, and vaccination costs alone.
Our analysis has limitations. PRIME does not model 
transmission of HPV infection or the natural history of 
precancerous cervical disease, and many of the 
parameters we use in this analysis are based on global 
datasets that extrapolate data from a small number of 
countries. PRIME also does not model introduction of 
non-vaccine interventions to reduce cervical cancer 
burden such as screening. Such interventions are 
important to consider alongside vaccination as part of a 
comprehensive strategy to control cervical cancer.30 
Hence, PRIME complements models that have additional 
features to accurately capture events such as herd 
(indirect) protection, changes to the prevalence of 
precancerous neoplasias, and other HPV-related 
endpoints including non-cervical cancers and anogenital 
warts. Such events are important to address more 
complex policy questions such as catch-up and male 
vaccination, the choice between bivalent and quadrivalent 
HPV vaccines, and the interaction between vaccination 
and screening when both are introduced around the 
same time. The advantage of PRIME is that it is 
straightforward enough to be used by non-experts and 
has fairly light data requirements. For example, estimates 
of population-based HPV prevalence or of cervical 
neoplasias (which are not available in most countries 
with a high burden of cervical cancer) are not required.
The potential eﬀ ect of exclusion of herd immunity is 
diﬃ  cult to estimate because published models do not 
disaggregate direct and indirect eﬀ ects on outcomes. 
One review9 of studies in high-income countries 
suggested that inclusion of indirect eﬀ ects decreased 
cost-eﬀ ectiveness ratios by 23–44%. A review in LMICs 
suggested much larger diﬀ erences, with median cost-
eﬀ ectiveness ratios of I$10 263 for static models and 
I$650 for dynamic models.8 However, between-model 
comparisons need to be treated with caution because 
Figure 4: (A) Number of GAVI-72 countries that have introduced human papillomavirus (HPV) vaccination, 
(B) annual number of girls vaccinated, (C) annual number of cervical cancers prevented, and (D) annual 
number of deaths prevented by vaccination in those countries
Three scenarios are shown: (1) no further vaccine introductions or increases in coverage beyond 2014 (worst case), 
(2) introductions according to GAVI strategic demand forecasts, and (3) the entire cohort of 12-year olds in every 
GAVI-72 country is vaccinated every year from 2014 (best case). Shaded regions show the range of results in 
sensitivity analyses when cancer incidence and mortality are varied by ±25%. A and B have no shaded regions 
because varying the epidemiological parameters has no eﬀ ect on the coverage of vaccination.
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models that realistically incorporate indirect eﬀ ects 
(dynamic models) are largely produced by a small 
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eﬀ ects) that diﬀ erentiate them from other models.
Our analysis suggests that the potential of HPV 
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